Company Description
PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States.
The company’s lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck.
Its product pipeline also comprises EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform.
The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York
| Country | United States |
| Founded | 2014 |
| IPO Date | Apr 28, 2016 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 39 |
| CEO | Lishan Aklog |
Contact Details
Address: 360 Madison Avenue, 25th Floor New York, New York 10017 United States | |
| Phone | 917 813 1828 |
| Website | pavmed.com |
Stock Details
| Ticker Symbol | PAVM |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001624326 |
| CUSIP Number | 70387R106 |
| ISIN Number | US70387R4039 |
| Employer ID | 47-1214177 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Lishan Aklog M.D. | Chairman and Chief Executive Officer |
| Dennis M. McGrath CPA | President and Chief Financial Officer |
| Shaun M. O'Neill M.B.A. | Executive Vice President and Chief Operating Officer |
| Michael Adam Gordon | Executive Vice President, General Counsel and Secretary |
| Dr. Brian J. deGuzman M.D. | Executive Vice President, Chief Technology and Compliance Officer |
| Dr. Suman M. Verma M.D., Ph.D. | Senior Vice President of Molecular Genetics and Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 13, 2025 | 8-K | Current Report |
| Nov 12, 2025 | 10-Q | Quarterly Report |
| Oct 31, 2025 | DEF 14A | Other definitive proxy statements |
| Oct 20, 2025 | PRE 14A | Other preliminary proxy statements |
| Sep 11, 2025 | 8-K | Current Report |
| Aug 14, 2025 | SCHEDULE 13G | Filing |
| Aug 14, 2025 | 8-K | Current Report |
| Aug 14, 2025 | 10-Q | Quarterly Report |
| Jul 30, 2025 | 8-K | Current Report |
| Jul 28, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |